prednisolone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 153 Diseases   74 Trials   74 Trials   10107 News 


«12345678910111213...8586»
  • ||||||||||  Recurrent Uvular Angioedema After Intranasal Cocaine Use (E-TPS Display Only Digital section) -  Apr 5, 2024 - Abstract #EAACI2024EAACI_482;    
    He promptly received epinephrine, benadryl, and solumedrol...The uvular edema resolved with a 3-day course of oral prednisolone...Our case is the first to illustrate a recurrent nature with continued use of cocaine. Cocaine should be considered as a causative agent in patients with uvular angioedema, and patients should be educated to avoid fatal complications.
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment open, Trial completion date, Trial primary completion date, Monotherapy:  Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy (clinicaltrials.gov) -  Apr 2, 2024   
    P4,  N=78, Recruiting, 
    Cocaine should be considered as a causative agent in patients with uvular angioedema, and patients should be educated to avoid fatal complications. Not yet recruiting --> Recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Sep 2026
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Facial cutaneous Rosai-Dorfman disease: a (Pubmed Central) -  Mar 31, 2024   
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Sep 2026 Although cutaneous Rosai-Dorfman disease is considered benign and well medical responded disease, patients with atypical presentation and rapid growing lesion may necessitate aggressive multimodal treatment.
  • ||||||||||  prednisolone / Generic mfg.
    IMPROVING PATIENT SAFETY VIA THE DEVELOPMENT OF A PHARMACIST-LED GLUCOCORTICOID COUNSELLING SERVICE (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2025;    
    Additionally, it enabled the identification and rectification of gaps in monitoring for adverse events and increased patient safety. Our service identified that providing patients with written information alone is inadequate and that counselling outside of the clinical consultation is effective and well-received by patients.
  • ||||||||||  Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
    ULTRASOUND REMISSION RATES AFTER 1 YEAR ARE HIGH IN EARLY RA PATIENTS ON INDUCTION TREATMENT: RESULTS FROM THE RANDOMIZED NORD-STAR TRIAL (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_756;    
    About 1 in 6 patients lost response with repeat cycles and this was associated with a 2NDNR phenomenon. Background: The randomized controlled NORD-STAR trial demonstrated remission rates of 40-60% in patients with early rheumatoid arthritis (RA) at 24 and 48 weeks according to the Clinical Disease Activity Index (CDAI) when treated early with methotrexate in combination with prednisolone (active conventional therapy (ACT)), certolizumab pegol (CZP), abatacept (ABA) or tocilizumab (TCZ) (1, 2)...Treatment-na
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Effect of Bacillus subtilis and Bacillus coagulans spores on induced allergic contact dermatitis in dogs. (Pubmed Central) -  Mar 23, 2024   
    Background: The randomized controlled NORD-STAR trial demonstrated remission rates of 40-60% in patients with early rheumatoid arthritis (RA) at 24 and 48 weeks according to the Clinical Disease Activity Index (CDAI) when treated early with methotrexate in combination with prednisolone (active conventional therapy (ACT)), certolizumab pegol (CZP), abatacept (ABA) or tocilizumab (TCZ) (1, 2)...Treatment-na According to the results, B. subtilis and B. coagulans can be further investigated as a viable alternative to corticosteroids in treating allergic contact dermatitis in dogs.
  • ||||||||||  prednisolone / Generic mfg.
    VITAMIN D TOXICITY  () -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_874;    
    Although our patient was only consuming 5000IU/day of Vitamin D for a year, we were concerned whether use of droplet formulations may lead to inconsistent dose administration. As hypervitaminosis D is rare, no consensus evidence-based guidelines are available.
  • ||||||||||  prednisolone / Generic mfg., methotrexate / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  PREDMETH: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis (clinicaltrials.gov) -  Mar 12, 2024   
    P4,  N=138, Active, not recruiting, 
    MLF contributes to body image disturbance and is associated with the development of GC-induced diabetes; therefore, it is clinically important as a physical manifestation of GC therapy. Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Jun 2023 --> Jul 2024
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    COMPARING HORSE VS RABBIT ATG AS INDUCTION THERAPY IN KIDNEY TRANSPLANT (MON-301; Exhibition Hall and Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1638;    
    We randomised all immunologically high risk patients(cadaver, spousal and approved unrelated transplants)to receive either Horse or Rabbit ATG from June 2023 to December 2023.They received Injection Horse ATG at the dose of 10 mg/kg body weight or 5mg/kg of Rabbit ATG.After induction ,maintenance therapy was continued with tablet prednisolone, mycophenolate mofetil and Tacrolimus.Patients were monitored for any infusion reactions and followed for a period of 3 months till March 2024 .Biopsy proven rejections, infections episodes were recorded. Till now the data analysed shows that patients receiving Horse ATG were performing well.There is no statistically significant difference in patients receiving horse vs rabbit ATG.If proven good horse ATG can replace rabbit ATG as a cheaper alternative as the overall cost of induction can be reduced upto one thirds.
  • ||||||||||  Remicade (infliximab) / J&J
    Trial completion:  Top-down Infliximab Study in Kids With Crohn's Disease (clinicaltrials.gov) -  Mar 5, 2024   
    P4,  N=100, Completed, 
    Till now the data analysed shows that patients receiving Horse ATG were performing well.There is no statistically significant difference in patients receiving horse vs rabbit ATG.If proven good horse ATG can replace rabbit ATG as a cheaper alternative as the overall cost of induction can be reduced upto one thirds. Active, not recruiting --> Completed
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Comparison of the effects of two different styles of orally prescribing prednisolone on postoperative sequelae of surgical extraction of an impacted mandibular third molar: a single-blind randomized study. (Pubmed Central) -  Feb 29, 2024   
    A randomized, split-mouth clinical study was conducted to investigate the efficacy of two different styles of preoral prednisolone in mitigating postoperative sequelae following surgical extraction of impacted mandibular third molars...Group A included those who received a single dose of prednisolone 25 mg, while group B received prednisolone 5 mg postoperatively for a period of three days (5 mg three times/day on the first postoperative day, 5 mg twice/day on the second postoperative day; 5 mg once/day on the third postoperative day). There was a significant difference in the distance between the corner of the mouth and tragus, which decreased with the time interval with respect to group B when compared to group A. The present study showed that a three-day tapered dose of prednisolone postoperatively was more effective in reducing post-extraction sequelae than a single-dose regimen.
  • ||||||||||  cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, HEOR, Metastases:  Tolerance: A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Feb 22, 2024   
    P3,  N=14, Terminated, 
    Active, not recruiting --> Completed N=185 --> 14 | Trial completion date: Mar 2027 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Sep 2023; Withdrawal grant provider
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
    A Combination of Tezepelumab and Omalizumab for Severe Persistent Asthma (San Diego Convention Center, Area H (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_5640;    
    A while Later she was started on Azathioprine and Theophylline which showed a good effect with decreased exacerbations...Subsequently, she was desensitized to IV hydrocortisone which helped in managing her acute exacerbations, and then desensitized to oral prednisolone and kept on it chronically which helped in preventing her exacerbations...DiscussionSince Tezepelumab was added to the regimen along with Omalizumab, the patient had fewer exacerbations to 2 times/year compared to the previous year with 6 exacerbations. Theophylline was stopped completely, and prednisolone was tapered to 5 mg daily, hoping that it could be stopped completely in the near future.
  • ||||||||||  prednisolone / Generic mfg., mycophenolate mofetil / Generic mfg.
    Cancrorum Ducere Fibra (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_1617;    
    The available literature on this anti-ku associated disease is sparse. The patient is being followed up for evolution of lung disease, evidence of new onset myositis and further association with malignancy.
  • ||||||||||  prednisolone / Generic mfg., prednisone / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, Head-to-Head:  ADAPTinMCN: Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy (clinicaltrials.gov) -  Feb 20, 2024   
    P4,  N=71, Active, not recruiting, 
    The patient is being followed up for evolution of lung disease, evidence of new onset myositis and further association with malignancy. Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2024 --> Feb 2024
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Checkpoint Inhibitor Immunotherapy Induced Inflammatory Arthritis Secondary to Nivolumab and Ipilumab: a Pediatric First () -  Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_172;    
    Her initial presentation was consistent with a grade 1 irAE with mild pain with clinical arthritis.1 She was initially treated with Naproxen with good improvement in pain; however, with each subsequent cycle of immunotherapy, her inflammatory arthritis worsened despite escalating naproxen doses. Her symptoms worsened to a grade 2 irAE with moderate pain and limitations in activities of daily living, resulting in her being started on oral prednisolone 0.5mg/kg/day, and her Naproxen was changed to Celebrex due to GI intolerance.1 As of her last follow-up, she had achieved clinical remission of her mesothelioma following six cycles of Nivolumab and Ipilumab and had control of her inflammatory arthritis on Celebrex monotherapy.
  • ||||||||||  prednisolone / Generic mfg.
    Enrollment open, Trial primary completion date:  PREMI: Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages (clinicaltrials.gov) -  Jan 31, 2024   
    P2,  N=490, Recruiting, 
    Her symptoms worsened to a grade 2 irAE with moderate pain and limitations in activities of daily living, resulting in her being started on oral prednisolone 0.5mg/kg/day, and her Naproxen was changed to Celebrex due to GI intolerance.1 As of her last follow-up, she had achieved clinical remission of her mesothelioma following six cycles of Nivolumab and Ipilumab and had control of her inflammatory arthritis on Celebrex monotherapy. Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2027 --> Jul 2026
  • ||||||||||  prednisolone / Generic mfg.
    First in human treatment of Crohn (Poster exhibition) -  Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1908;    
    1 patient started oral prednisolone at wk 6 for active disease...Clinical and endoscopic changes should be interpreted with caution in such small numbers of patients. There is a rationale to proceed to Ph2.
  • ||||||||||  Fasenra (benralizumab) / AstraZeneca
    Enrollment closed:  Acute Exacerbations Treated With BenRAlizumab (The ABRA Study) (clinicaltrials.gov) -  Jan 23, 2024   
    P2,  N=158, Active, not recruiting, 
    Most importantly, no mortality or development of end-stage renal disease was observed in the rituximab-treated cohort. Recruiting --> Active, not recruiting
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Journal:  State-of-the-art paradigm of corticosteroid therapy for immune-mediated inflammatory kidney diseases (Pubmed Central) -  Jan 6, 2024   
    A combination of calcineurin inhibitors and low-dose CS are effective for remission induction in membranous nephropathy, as well as the steroid-free rituximab regimen for the patients with moderate risk of disease progression...Thus, overall trend is directed towards the minimization of the maximal doses of CS and/or treatment duration. However, to implement this approach morphological verification of the diagnosis and personalized assessment of the potential risk and benefit are required.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment open, Trial initiation date:  Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss (EUDRACT) -  Dec 1, 2023   
    P4,  N=200, Recruiting, 
    DNASE2 deficiency should be suspected in patients with early-onset lupus with polyarthritis, erythematous rash, and neurological involvement. Not yet recruiting --> Recruiting